Healthcare & Life Sciences

The US healthcare sector, particularly biotech and life sciences, receives massive allocations from Mubadala and ADQ. The focus is on therapeutics, digital health, and specialized manufacturing.

Mubadala frequently co-invests with specialized healthcare PE firms, while ADQ looks for synergistic assets that can plug into its domestic Pure Health network.

Sector Deep Dive & FAQ

Common Mistakes

Assuming all Abu Dhabi funds share the same risk mandate.
Overlooking the impact of CFIUS on direct equity ownership.
Treating ADQ's operational focus as standard private equity.

Frequently Asked Questions

What is the scale of these investments?: As of Q1 2024, combined estimated AUM exceeds $1.5T.
Why the US market?: Unmatched depth, liquidity, and access to deep tech.

Worked Example: Co-Investment Sizing

If a sovereign fund commits $500M directly alongside a US sponsor in a mega-buyout (bypassing the standard 20% carry on a 2x return), they save approximately $100M in performance fees.

Source: Proprietary estimates based on 2023 mega-fund structures.

Natural Next Step

To understand how these funds mitigate regulatory friction when deploying this capital, review our guide on Navigating CFIUS.